Bronchiectasis (Respiratory) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis – Drugs In Development, 2021, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 6, 9 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).

– The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Alaxia SAS

Alitair Pharmaceuticals Inc

Armata Pharmaceuticals

Boehringer Ingelheim International GmbH

Chiesi Farmaceutici SpA

Cila Therapeutics

CSL Ltd

Destiny Pharma Plc

Helperby Therapeutics Group Ltd

Insmed Inc

Kamada Pharmaceuticals

Kyowa Kirin Co Ltd

MDI Therapeutics Inc

Novabiotics Ltd

Novartis AG

OrPro Therapeutics Inc

Parion Sciences Inc

Polyphor Ltd

PureIMS BV

Recipharm AB

Renovion Inc

Santhera Pharmaceuticals Holding AG

Table of Contents

Table of Contents

Introduction

Bronchiectasis - Overview

Bronchiectasis - Therapeutics Development

Bronchiectasis - Therapeutics Assessment

Bronchiectasis - Companies Involved in Therapeutics Development

Bronchiectasis - Drug Profiles

Bronchiectasis - Dormant Projects

Bronchiectasis - Discontinued Products

Bronchiectasis - Product Development Milestonesh

Appendix

List of Tables

List of Tables

Number of Products under Development for Bronchiectasis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Bronchiectasis – Pipeline by Alaxia SAS, 2021

Bronchiectasis – Pipeline by Alitair Pharmaceuticals Inc, 2021

Bronchiectasis – Pipeline by Armata Pharmaceuticals, 2021

Bronchiectasis – Pipeline by Boehringer Ingelheim International GmbH, 2021

Bronchiectasis – Pipeline by Chiesi Farmaceutici SpA, 2021

Bronchiectasis – Pipeline by Cila Therapeutics, 2021

Bronchiectasis – Pipeline by CSL Ltd, 2021

Bronchiectasis – Pipeline by Destiny Pharma Plc, 2021

Bronchiectasis – Pipeline by Helperby Therapeutics Group Ltd, 2021

Bronchiectasis – Pipeline by Insmed Inc, 2021

Bronchiectasis – Pipeline by Kamada Pharmaceuticals, 2021

Bronchiectasis – Dormant Projects, 2021

Bronchiectasis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Bronchiectasis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports